Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are set to open sharply lower on Friday, plummeting 32.18% in pre-market trading following the release of disappointing first-quarter 2025 financial results and a downward revision of its full-year guidance.
The clinical-stage biotechnology company reported a quarterly loss of $0.36 per share, significantly missing the analyst consensus estimate of $0.24 per share. While this represents a 14.29% improvement from the $0.42 loss per share in the same quarter last year, it fell short of market expectations. Revenue for the quarter came in at $49.32 million, falling well below the analyst forecast of $81.70 million by 39.63%.
Adding to investor concerns, Iovance Biotherapeutics revised its fiscal year 2025 total product revenue guidance to a range of $250 million to $300 million, down from previous projections. The company's net loss for the quarter stood at $116.163 million, with an operating loss of $121.221 million. These figures, coupled with the lowered guidance, have shaken investor confidence in the company's near-term growth prospects and its path to profitability, leading to the significant pre-market sell-off.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.